Clinical Trial Update: A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial updating safety of nivolumab plus ipilimumab in previously untreated advanced or metastatic renal cell carcinoma; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Renal Cell Carcinoma | Phase 4 | Status: COMPLETED | Results posted: 2021-10-14